Home  /  Resource Library  /  Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma

Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma

Match comparison study examined mosunetuzumab versus CAR T lisocabtagene maraleucel for treatment of relapsed follicular lymphoma.